Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom Index.
Magasi S, Mallick R, Kaiser K, Patel JD, Lad T, Johnson ML, Kaplan EH, Cella D. Magasi S, et al. Among authors: patel jd. Clin Lung Cancer. 2013 May;14(3):245-53. doi: 10.1016/j.cllc.2012.07.001. Epub 2012 Oct 1. Clin Lung Cancer. 2013. PMID: 23036663
Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C, Cagle PT, Johnson M, Patel JD, Yeldandi AV, Raj R, DeCamp MM, Raparia K. Villa C, et al. Among authors: patel jd. Arch Pathol Lab Med. 2014 Oct;138(10):1353-7. doi: 10.5858/arpa.2013-0376-OA. Epub 2014 Feb 26. Arch Pathol Lab Med. 2014. PMID: 24571650 Free article.
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC. Patel JD, et al. Clin Lung Cancer. 2009 Jul;10(4):252-6. doi: 10.3816/CLC.2009.n.035. Clin Lung Cancer. 2009. PMID: 19632943 Clinical Trial.
A brief symptom index for advanced lung cancer.
Yount S, Beaumont J, Rosenbloom S, Cella D, Patel J, Hensing T, Jacobsen PB, Syrjala K, Abernethy AP. Yount S, et al. Clin Lung Cancer. 2012 Jan;13(1):14-23. doi: 10.1016/j.cllc.2011.03.033. Epub 2011 May 23. Clin Lung Cancer. 2012. PMID: 21729652 Free PMC article.
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Reynolds CH, et al. Among authors: patel jd. Clin Lung Cancer. 2015 May;16(3):200-8. doi: 10.1016/j.cllc.2014.11.004. Epub 2014 Nov 18. Clin Lung Cancer. 2015. PMID: 25516338 Clinical Trial.
200 results